Request for Information on Implementation of the James Zadroga 9/11 Health and Compensation Act of 2010 (Pub. L. 111-347), 12360-12361 [2011-5111]
Download as PDF
<![CDATA[
12360
Federal Register / Vol. 76, No. 44 / Monday, March 7, 2011 / Notices
understand and respond appropriately.
The project activities and methods will
remain the same as those used in the
previously approved collection.
Data are collected through
anonymous, in-person interviews
conducted with persons systematically
selected from 25 Metropolitan Statistical
Areas (MSAs) throughout the United
States; these 25 MSAs were chosen
based on having high AIDS prevalence.
Persons at risk for HIV infection to be
interviewed for NHBS include men who
have sex with men (MSM), injecting
drug users (IDUs), and heterosexuals at
increased risk of HIV (HET). A brief
screening interview will be used to
determine eligibility for participation in
the behavioral assessment. The data
from the behavioral assessment will
provide estimates of behavior related to
the risk of HIV and other sexually
transmitted diseases, prior testing for
HIV, and use of HIV prevention
services. All persons interviewed will
also be offered an HIV test and will
participate in a pre-test counseling
session. No other federal agency
systematically collects this type of
information from persons at risk for HIV
infection. These data have substantial
impact on prevention program
development and monitoring at the
local, state, and national levels.
CDC estimates that NHBS will
involve, per year in each of the 25
MSAs, eligibility screening for 50 to 200
persons and eligibility screening plus
the survey with 500 eligible
respondents, resulting in a total of
37,500 eligible survey respondents and
7,500 ineligible screened persons during
a 3-year period. Data collection will
rotate such that interviews will be
conducted among one group per year:
MSM in year 1, IDU in year 2, and HET
in year 3. The type of data collected for
each group will vary slightly due to
different sampling methods and risk
characteristics of the group.
This request is for a revision and an
approval for an additional 3 years of
data collection. Participation of
respondents is voluntary and there is no
cost to the respondents other than their
time. The total estimated annualized
burden hours are 9,931.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Year 1 (MSM):
Persons Screened ...............................................................
Eligible Participants .............................................................
Year 2 (IDU):
Persons Referred by Peer Recruiters .................................
Eligible Participants .............................................................
Peer Recruiters ...................................................................
Year 3 (HET):
Persons Referred by Peer Recruiters .................................
Eligible Participants .............................................................
Peer Recruiters ...................................................................
Petunia Gissendaner,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2011–5092 Filed 3–4–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number NIOSH–226]
Request for Information on
Implementation of the James Zadroga
9/11 Health and Compensation Act of
2010 (Pub. L. 111–347)
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of public comment
period.
srobinson on DSKHWCL6B1PROD with NOTICES
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) requests
SUMMARY:
VerDate Mar<15>2010
17:54 Mar 04, 2011
Jkt 223001
Number of
respondents
Form name
Frm 00046
Average burden
per response; (in
hours)
Screener .................
Survey .....................
17,500
12,500
1
1
5/60
30/60
Screener .................
Survey .....................
Recruiter Debriefing
13,750
12,500
6,250
1
1
1
5/60
54/60
2/60
Screener .................
Survey .....................
Recruiter Debriefing
13,750
12,500
6,250
1
1
1
5/60
39/60
2/60
comments from the public on
implementing the provisions of the
James Zadroga 9/11 Health and
Compensation Act of 2010 (Pub. L. 111–
347). A copy of the Act is posted on the
Internet at https://www.cdc.gov/niosh/
docket in the NIOSH Docket number
226. The Federal government is
developing an implementation plan,
and comments from the public will
assist in this process by gaining
perspectives from interested parties on
ways to meet the Act’s requirements.
The public is invited to submit written
comments to the NIOSH Docket number
226. A public meeting on March 3,
2011, was previously announced in the
Federal Register (76 FR 7862) on
February 11, 2011 to accept oral
comments from the public.
Public Comment Period: All
comments must be received by April 29,
2011.
ADDRESSES: Written comments may be
submitted to the NIOSH Docket Office,
identified by Docket number NIOSH–
226, by any of the following methods:
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C34, 4676
Columbia Parkway, Cincinnati, OH
45226.
PO 00000
Responses per
respondent
Fmt 4703
Sfmt 4703
• Facsimile: (513) 533–8285.
• E-mail: nioshdocket@cdc.gov.
All information received in response
to this notice will be available for public
examination and copying at the NIOSH
Docket Office, Room 111, 4676
Columbia Parkway, Cincinnati, Ohio
45226.
A complete electronic docket
containing a copy of the James Zadroga
9/11 Health and Compensation Act of
2010 (Pub. L. 111–347) and all
comments submitted will be available
on the NIOSH Web site at https://
www.cdc.gov/niosh/docket. All
comments received will be available for
public inspection, including any
personally identifiable or confidential
business information that is included in
a comment. Because comments will be
made public, they should not include
any sensitive personal information, such
as a person’s social security number;
date of birth; driver’s license number;
state identification number or foreign
country equivalent; passport number;
financial account number; or credit or
debit card number. Comments also
should not include any sensitive health
information, such as medical records or
other individually identifiable health
E:\FR\FM\07MRN1.SGM
07MRN1
Federal Register / Vol. 76, No. 44 / Monday, March 7, 2011 / Notices
information, or any non-public
corporate or trade association
information, such as trade secrets or
other proprietary information.
Roy
Fleming, Sc.D., CDC/NIOSH, 1600
Clifton Road, NE., MS–E20, Atlanta,
Georgia 30333, Toll free 1–866–426–
3673, e-mail: nioshdocket@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
Dated: February 28, 2011.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2011–5111 Filed 3–4–11; 8:45 am]
BILLING CODE 4163–19–P
Centers for Disease Control and
Prevention
[Docket Number NIOSH 134–A]
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) seeks
comment on the types of hazard
identification and risk management
research that should be considered for
updating the NIOSH 2009
nanotechnology strategic plan.
Public Comment Period: Comments
must be received by April 15, 2011.
ADDRESSES: Written comments,
identified by docket number NIOSH
134–A, may be submitted by any of the
following ways:
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C–34, 4676
Columbia Parkway, Cincinnati, Ohio
45226.
• Facsimile: (513) 533–8285.
• E-mail: nioshdocket@cdc.gov.
All information received in response
to this notice will be available for public
examination and copying at the NIOSH
Docket Office, 4676 Columbia Parkway,
Room 109, Cincinnati, Ohio 45226. A
complete electronic docket containing
all comments submitted will be
available thirty days after the public
comment period on the NIOSH Web
page at https://www.cdc.gov/niosh/
docket, and comments will be available
in writing by request. NIOSH includes
all comments received without change
in the docket, including any personal
information provided. All electronic
comments should be formatted as
Microsoft Word. Please make reference
to docket number NIOSH 134–A.
SUMMARY:
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
srobinson on DSKHWCL6B1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of public comment
period.
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Determine of
the Benefits of Work and/or School
Exclusion to Respiratory Illness in
Decreasing Influenza Transmission,
Funding Opportunity Number (FOA)
CK11–007, Initial Review
Time and Date: 8 a.m.–5 p.m., May 2, 2011
(Closed).
Place: Sheraton Gateway Hotel Atlanta
Airport, 1900 Sullivan Road, Atlanta, Georgia
30337, Telephone: (770) 997–1100.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: [The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Determine of the Benefits of
work and/or School Exclusion to Respiratory
Illness in Decreasing Influenza
Transmission’’]
Contact Person for More Information: Dr.
Amy Yang, Scientific Review Officer, CDC,
1600 Clifton Road, NE., Mailstop E60,
Atlanta, Georgia 30333, Telephone: (404)
498–2733.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Jkt 223001
BILLING CODE 4163–18–P
AGENCY:
Centers for Disease Control and
Prevention
17:54 Mar 04, 2011
[FR Doc. 2011–5102 Filed 3–4–11; 8:45 am]
Request for Information: Update of
NIOSH Nanotechnology Strategic Plan
for Research and Guidance
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Mar<15>2010
Dated: February 25, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
12361
Background: Since 2004, the National
Institute for Occupational Safety and
Health (NIOSH) of the Centers for
Disease Control and Prevention (CDC)
has pioneered research on the
toxicological properties and
characteristics of nanoparticles. This
research has involved characterizing
occupationally relevant nanoparticles
for predicting whether these particles
pose a risk of adverse health effects and
for providing guidance on controlling
workplace exposures. In September
2005, NIOSH developed a strategic plan
to further guide the Institute in
identifying and prioritizing
nanotechnology research. In 2009 this
strategic plan [https://www.cdc.gov/
niosh/topics/nanotech/strat_plan.html]
was updated based on knowledge
gained from results of ongoing NIOSH
research [see Progress Toward Safe
Nanotechnology in the Workplace; A
Report from the NIOSH Nanotechnology
Research Center https://www.cdc.gov/
niosh/docs/2007–123/] and from
stakeholder input.
NIOSH would like to build on the
accomplishments of ongoing research
[see https://www.cdc.gov/niosh/docs/
2010–104/] to develop strategic research
goals and objectives through 2015.
NIOSH has identified 10 critical
research areas for nanotechnology
research and communication. These 10
critical research areas are (1) toxicity
and internal dose, (2) measurement
methods, (3) exposure assessment, (4)
epidemiology and surveillance, (5) risk
assessment, (6) engineering controls and
personal protective equipment (PPE), (7)
fire and explosion safety, (8)
recommendations and guidance, (9)
communication and information, and
(10) applications.
NIOSH is considering focusing the
overarching strategic research goals for
these critical areas on 5 key goals: (1)
Provide guidance to protect workers, (2)
alert workers, employers, governments,
and the public about possible new
hazards, (3) assess the hazards of
nanomaterials and the risks to workers,
(4) help workers by assessing and
implementing exposure registries, and
(5) assess the level of protection
practiced in US workplaces.
NIOSH requests comment on how
research in these 10 critical areas and
the 5 overarching goals can be
enhanced. Examples of requested
information include, but are not limited
to:
(1) The need for toxicity evaluation
and/or workplace exposure
characterization of engineered
nanoparticles not currently being
studied*.
E:\FR\FM\07MRN1.SGM
07MRN1
]]>Agencies
[Federal Register Volume 76, Number 44 (Monday, March 7, 2011)]
[Notices]
[Pages 12360-12361]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-5111]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number NIOSH-226]
Request for Information on Implementation of the James Zadroga 9/
11 Health and Compensation Act of 2010 (Pub. L. 111-347)
AGENCY: National Institute for Occupational Safety and Health (NIOSH),
Centers for Disease Control and Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of public comment period.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC)
requests comments from the public on implementing the provisions of the
James Zadroga 9/11 Health and Compensation Act of 2010 (Pub. L. 111-
347). A copy of the Act is posted on the Internet at https://www.cdc.gov/niosh/docket in the NIOSH Docket number 226. The Federal
government is developing an implementation plan, and comments from the
public will assist in this process by gaining perspectives from
interested parties on ways to meet the Act's requirements. The public
is invited to submit written comments to the NIOSH Docket number 226. A
public meeting on March 3, 2011, was previously announced in the
Federal Register (76 FR 7862) on February 11, 2011 to accept oral
comments from the public.
Public Comment Period: All comments must be received by April 29,
2011.
ADDRESSES: Written comments may be submitted to the NIOSH Docket
Office, identified by Docket number NIOSH-226, by any of the following
methods:
Mail: NIOSH Docket Office, Robert A. Taft Laboratories,
MS-C34, 4676 Columbia Parkway, Cincinnati, OH 45226.
Facsimile: (513) 533-8285.
E-mail: nioshdocket@cdc.gov.
All information received in response to this notice will be
available for public examination and copying at the NIOSH Docket
Office, Room 111, 4676 Columbia Parkway, Cincinnati, Ohio 45226.
A complete electronic docket containing a copy of the James Zadroga
9/11 Health and Compensation Act of 2010 (Pub. L. 111-347) and all
comments submitted will be available on the NIOSH Web site at https://www.cdc.gov/niosh/docket. All comments received will be available for
public inspection, including any personally identifiable or
confidential business information that is included in a comment.
Because comments will be made public, they should not include any
sensitive personal information, such as a person's social security
number; date of birth; driver's license number; state identification
number or foreign country equivalent; passport number; financial
account number; or credit or debit card number. Comments also should
not include any sensitive health information, such as medical records
or other individually identifiable health
[[Page 12361]]
information, or any non-public corporate or trade association
information, such as trade secrets or other proprietary information.
FOR FURTHER INFORMATION CONTACT: Roy Fleming, Sc.D., CDC/NIOSH, 1600
Clifton Road, NE., MS-E20, Atlanta, Georgia 30333, Toll free 1-866-426-
3673, e-mail: nioshdocket@cdc.gov.
Dated: February 28, 2011.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2011-5111 Filed 3-4-11; 8:45 am]
BILLING CODE 4163-19-P
